Drug-labelled 89Zirconium-Atezolizumab, including participants with NSCLC, bladder and breast cancers, demonstrated better prediction of clinical response using mean SUVmax on PET compared with either SP263 or SP142 PD-L1 immunohistochemical assays [18]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.